Disposable Endoscopes Market Size & Share 2026-2035

Disposable Endoscopes Market Size

The global disposable endoscopes market was valued at USD 2.2 billion in 2025 and is projected to reach USD 9.2 billion by 2035, expanding at a CAGR of 15.7% over 2026–2035. According to the latest report published by Global Market Insights Inc., the market reaches USD 2.5 billion in 2026.

Disposable endoscopes include sterile, single-use flexible scopes used across respiratory, gastrointestinal, urological, gynecological, airway-management, and related procedures. The scope excludes conventional reusable endoscope revenues, reusable capital towers sold independently of single-use platforms, and non-endoscopic disposable accessories. The market has moved beyond a narrow infection-control niche. Hospital purchasing teams increasingly evaluate single-use scopes against the combined burden of reprocessing labor, capital replacement, procedure-room turnover, and infection-event exposure. That shift changes the commercial comparison from unit price to procedure economics. It also directs demand toward platforms that connect several disposable devices to a common imaging and documentation environment.

Market estimates use triangulation across product-level adoption, procedure settings, regional purchasing patterns, and competitive portfolio coverage. The 2025 base year anchors the forecast, while the 2026–2035 outlook reflects the adoption trajectory across hospitals, ambulatory surgical centers (ASCs), and other end users. Market values are expressed in USD million or USD billion as indicated.

Key Drivers

Rising Incidence of Gastrointestinal Disorders, Cancer, and Chronic Conditions

Colorectal cancer accounted for more than 1.9 million new cases worldwide in 2022.^{[1]World Health Organization, who.int} Surveillance, diagnostic, and staging activity creates repeat demand for endoscopic access across hospital and outpatient settings. Inflammatory bowel disease, Barrett’s esophagus, chronic respiratory disease, and cancer screening increase the procedural base for bronchoscopy, cystoscopy, and upper-GI procedures. Aging populations in North America, Western Europe, and Northeast Asia concentrate this demand in regions with the strongest disposable-scope purchasing capacity. North America consequently held 49.93% of global market revenue in 2025.

Increasing Demand for Minimally Invasive Procedures

Endoscopic approaches to stone removal, biopsy, polypectomy, and bronchoscopic intervention support shorter stays, lower complication risk, and faster return to normal activity than open alternatives.^{[3]American College of Surgeons, facs.org} Payers and providers in the United States, the United Kingdom, and Germany have continued shifting appropriate procedures toward ambulatory settings. Single-use devices fit this transition because they remove reprocessing workflow from sites that need rapid room turnover. Ureteroscopy illustrates the effect: its product segment is projected to grow at a 15.9% CAGR through 2035 as minimally invasive stone management expands.

Technological Advancements in Disposable Endoscopes

Recent devices have narrowed the early performance gap between reusable and single-use scopes. Ambu launched the aScope 5 Broncho HD in February 2025 with a 5.6 mm insertion tube and a 2.8 mm working channel. Karl Storz received FDA 510(k) clearance for the FIVE S 6.5 in March 2026; its 3.0 mm channel can clear 15 mL of simulated mucus in under five seconds.^{[7]U.S. Food and Drug Administration - Device Approvals and Clearances (510(k) Database), fda.gov} These specifications address a material critical-care objection to earlier single-use bronchoscope designs. Shared digital towers and multi-scope connectivity further reduce the capital complexity of portfolio-wide conversion.

Increased Focus on Contamination and Infection Control

Reusable duodenoscope reprocessing remains a persistent clinical and regulatory concern. The FDA has issued safety communications on transmission risks associated with contaminated reusable duodenoscopes, including carbapenem-resistant Enterobacteriaceae.^{[4]U.S. Food and Drug Administration - Safety Communications on Endoscope Reprocessing and Infection Risk, fda.gov} Federal health data indicates that 15.2% of reusable duodenoscopes may retain viable microbial contamination after enhanced cleaning protocols. Teaching hospitals and complex-care centers have therefore accelerated use of single-use duodenoscopes, bronchoscopes, and ureteroscopes where infection exposure and clinical liability are highest.

Key Restraints

Shortage of Skilled Physicians and Endoscopists

The supply of trained endoscopists limits the pace at which procedure volume can expand, especially in lower- and middle-income markets.^{[8]Robert Koch Institut, rki.de} Advanced procedures such as endoscopic ultrasound, per-oral endoscopic myotomy, and bronchoscopic navigation require training that extends beyond basic diagnostic use. Facilities can procure scopes faster than they can expand specialist capacity. Simulation platforms and accelerated curricula offer mitigation, but workforce constraints are likely to limit addressable procedure growth through 2028–2029.

Higher Per-Procedure Cost Relative to Reusable Platforms

A single-use scope typically costs USD 60–350, depending on device type and complexity.^{[5]Organisation for Economic Co-operation and Development, oecd.org} The cost premium matters most in high-volume facilities that have already amortized reusable-device infrastructure. Procurement decisions increasingly depend on total cost of ownership, including reprocessing labor, maintenance, capital replacement, quality assurance, and infection-event exposure. That calculus favors disposable devices in several complex-use categories, but unit cost remains a barrier in markets with weak reimbursement alignment.

Environmental and Waste Management Concerns

Single-use scopes create more medical waste per procedure than reusable alternatives. The Circular Economy Action Plan and relevant EU Green Deal provisions have raised sustainability scrutiny for manufacturers and health systems in Europe.^{[6]European Commission, ec.europa.eu} Procurement criteria in Germany, the Netherlands, and the United Kingdom increasingly account for lifecycle environmental impact. Materials innovation and take-back programs can mitigate the issue, but waste management will continue to slow adoption in tightly regulated markets.

GMI Analyst View

Disposable Endoscopes Market Segment Analysis

By Product Type

Bronchoscopes

Bronchoscopes were the largest product category, accounting for 35.52% of 2025 revenue, or approximately USD 781 million, and are projected to grow at a 16.2% CAGR through 2035. Respiratory disease, lung-cancer evaluation, ICU use, and infection-control priorities sustain the segment’s demand base. Ambu’s aScope 5 Broncho HD, Boston Scientific’s Exalt Model B, Verathon’s B-Flex 2, and Karl Storz’s FIVE S 6.5 define the highest-visibility commercial platforms. The FIVE S 6.5 adds a 3.0 mm working channel for secretion management, while the aScope 5 Broncho HD pairs a 5.6 mm insertion tube with a 2.8 mm channel. Comparative literature has reported performance equivalence across six commercially available single-use bronchoscope models in bronchoalveolar lavage scenarios.^{[10]Journal of Thoracic Disease, jtd.amegroups.org}

Cystoscopes

Cystoscopes accounted for 7.32% of 2025 revenue, or approximately USD 161 million, and are forecast to advance at a 15.8% CAGR. Bladder-cancer surveillance creates recurrent procedure demand, with monitoring intervals ranging from three to 12 months for patients on active surveillance.^{[12]National Institute of Diabetes and Digestive and Kidney Diseases, niddk.nih.gov} Ambu’s aScope 4 Cysto and aScope 5 Cysto HD provide established single-use options. Zenflow received FDA 510(k) clearance in September 2025 for the Spring Scope, a single-use cystoscope with a 12 French working channel that is more than 80% larger than previous single-use models.^{[7]U.S. Food and Drug Administration - Device Approvals and Clearances (510(k) Database), fda.gov} This device expansion moves the category toward therapeutic use cases that previously required reusable platforms.

Duodenoscopes

Duodenoscopes represented 9.54% of 2025 market revenue, or approximately USD 210 million, and are projected to grow at a 15.0% CAGR. Their lower growth rate reflects deeper conversion in high-risk U.S. and Western European ERCP settings. Boston Scientific’s EXALT Model D remains the reference platform for single-use duodenoscopy. The remaining commercial opportunity lies in community hospitals and regions where reprocessing risk has not yet translated into immediate conversion. Dragonfly Endoscopy’s 360° Rotatable Pancreaticobiliary Scope, FDA-cleared in 2025, extends single-use cholangioscopy into complex pancreaticobiliary procedures.^{[7]U.S. Food and Drug Administration - Device Approvals and Clearances (510(k) Database), fda.gov}

Hysteroscopes

Hysteroscopes accounted for 8.34% of 2025 revenue, approximately USD 183 million, and are forecast to expand at a 15.1% CAGR. The segment serves assessment and treatment of endometrial polyps, submucosal fibroids, abnormal uterine bleeding, and related gynecological conditions. Karl Storz’s ENDOCRAFT series and CooperSurgical’s TRUCLEAR system support office-based and ambulatory workflows. Compact single-use systems reduce the need for reprocessing infrastructure in specialist clinics. The United Kingdom’s NHS Gynaecology Improvement Programme adds a regional volume-support mechanism.^{[9]NHS England, england.nhs.uk}

Laryngoscopes

Laryngoscopes represented 11.07% of 2025 revenue, approximately USD 243 million, and are set to grow at a 15.4% CAGR. Demand comes from operating-room anesthesia, emergency airway access, and critical care, where shared-equipment contamination remains a concern. Ambu’s video-laryngoscope offerings and Verathon’s airway-management platforms are prominent in this category. Portable tower integration also supports use in pre-hospital emergency medicine and military casualty care. The persistent use of single-use video laryngoscopes after the COVID-19 period shows that infection-prevention protocols have become embedded in institutional practice.

Ureteroscopes

Ureteroscopes accounted for 15.10% of 2025 revenue, or approximately USD 332 million, and will expand at a 15.9% CAGR through 2035. Rising nephrolithiasis increases procedure demand, while ureteroscopic lithotripsy continues to displace extracorporeal shock wave lithotripsy in larger stone categories.^{[12]National Institute of Diabetes and Digestive and Kidney Diseases, niddk.nih.gov} Ambu’s aScope 5 Uretero and Olympus’s RenaFlex are leading single-use platforms; RenaFlex received FDA clearance in April 2024. Ambu’s expanded clearance for the aScope 5 Cysto HD supports combined ureteroscopy and percutaneous nephrolithotomy workflows. The category therefore benefits from both stone-disease volume and higher procedural completeness per case.

Other Product Types

Other product types, including gastroscopes, colonoscopes, nasopharyngoscopes, and arthroscopes, held 13.11% of 2025 revenue, or approximately USD 288 million. The category is projected to advance at a 14.7% CAGR, reflecting earlier commercial maturity in single-use gastroscopy and colonoscopy. Ambu’s aScope Gastro and Olympus’s H-SteriScope are key platforms. GI endoscopy offers the largest future volume opportunity, but requires broader clinical, reimbursement, and workflow conversion than bronchoscopy. Hybrid ENT-flex scopes are also supporting office-based otolaryngology use, while single-use arthroscopy remains an early investment area for high-acuity ASC settings.

By Clinical Use

Diagnostic

Diagnostic procedures held 61.81% of global revenue in 2025, approximately USD 1.36 billion, and are forecast to grow at a 15.5% CAGR. The segment includes bronchoscopy for lung-cancer evaluation, upper-GI endoscopy, colorectal screening, bladder-cancer monitoring, and hysteroscopy. U.S. screening guidance lowered the recommended colorectal-cancer screening age to 45, increasing the eligible population by an estimated 21 million individuals. AI-assisted lesion detection can enhance clinical yield and reinforce the value proposition for single-use imaging systems. This large recurring procedure base makes diagnostic adoption the principal volume anchor for the market. ^{[11]American Society for Gastrointestinal Endoscopy, asge.org}

Surgical

Surgical use represented 38.19% of 2025 revenue, approximately USD 840 million, and carries the higher clinical-use CAGR of 16.0%. ERCP, cholangioscopy, ureteroscopic lithotripsy, bronchoscopic biopsy, and operative hysteroscopy are central applications. Compatible disposable biopsy forceps, retrieval baskets, and stone-extraction devices strengthen the completeness of fully disposable procedure sets. The CMS outpatient procedures list continues to support migration of selected endoscopic interventions from inpatient settings. Surgical growth therefore reflects both higher revenue per procedure and a widening range of therapy-ready single-use systems.

By End Use

Hospitals

Hospitals held 63.81% of 2025 revenue, approximately USD 1.40 billion, and are projected to grow at a 15.5% CAGR. Pulmonology, critical care, gastroenterology, hepatology, and urology form the core hospital demand centers. Academic and tertiary hospitals were early adopters because they combine high procedure volume, immunocompromised patient populations, and stringent infection-control standards. Institutional purchasing scale can also improve per-unit pricing. Hospitals will remain the market’s largest revenue channel, but incremental growth increasingly depends on filling underconverted GI, urology, and ASC-adjacent use cases.

Ambulatory Surgical Centers

ASCs accounted for 28.40% of 2025 revenue, approximately USD 625 million, and are projected to grow at a 16.3% CAGR. They benefit from payer incentives for lower-cost sites of care, patient preference for same-day discharge, and the need to maximize suite utilization. Single-use devices eliminate reprocessing labor, capital expenditure, and related quality-assurance infrastructure. Ambu’s aView 2 Advance and aBox 2 platforms support multiscope visualization during combined urological procedures. The ASC segment thus converts the single-use proposition from a safety premium into a throughput and capital-efficiency decision.

Other End Users

Other end users, comprising specialist offices, outpatient clinics, military and defense medical facilities, and veterinary settings, represented 7.79% of 2025 revenue, or approximately USD 171 million. The segment is forecast to grow at a 14.2% CAGR. Fragmented purchasing and lower procedure volume constrain conversion, but physician offices avoid the fixed cost of reusable-scope reprocessing. Military facilities in NATO member countries use single-use bronchoscopes and laryngoscopes where decontamination infrastructure is unavailable. This channel remains smaller, but offers specialized demand where portability and sterility outweigh unit-price sensitivity.

Disposable Endoscopes Market Regional Analysis

North America

North America accounted for 49.93% of global revenue in 2025, approximately USD 1.10 billion, and is projected to grow at a 14.7% CAGR through 2035. The United States drives regional demand through broad FDA-cleared product availability, group purchasing organization access, and reimbursement structures that favor outpatient endoscopic care. FDA safety communications on reusable duodenoscope contamination created a strong institutional rationale for conversion in high-risk ERCP procedures.^{[4]U.S. Food and Drug Administration - Safety Communications on Endoscope Reprocessing and Infection Risk, fda.gov} Ambu’s collaboration with Vizient provides its single-use portfolio access to a national hospital network through a pre-negotiated supply framework. Canada contributes through provincial infection-control procurement criteria in Ontario and British Columbia that took effect in 2024. ^{[13]OECD Health Statistics - Healthcare Resources and Expenditure Data, oecd.org}

Europe

Europe held 33.33% of 2025 global revenue, approximately USD 733 million, and is expected to expand at a 15.2% CAGR. Germany, the United Kingdom, France, the Netherlands, and the Nordics form the advanced adoption tier, while Spain, Italy, Poland, and the Czech Republic remain earlier in the reimbursement and procurement transition. Germany’s hospital hygiene rules and Robert Koch Institut guidance support infection-control investment.^{[8]Robert Koch Institut, rki.de} NHS Supply Chain frameworks have lowered procurement friction for selected single-use bronchoscopes and laryngoscopes in the United Kingdom.^{[9]NHS England, england.nhs.uk} MDR 2017/745, fully applicable since May 2021, increases post-market surveillance and clinical-evidence requirements and favors companies with established regulatory capabilities. Pentax Medical launched ONE Pulmo in Europe in January 2025, demonstrating sustained supplier investment.

Rest of World

Rest of World accounted for 16.74% of 2025 revenue, approximately USD 368 million, and is set to grow at an 18.7% CAGR, the fastest regional pace. Asia Pacific drives current procedure volume and investment momentum. China combines large procedure demand with domestic supply from HugeMed, Vathin Medical, UE Medical, and TSC. India represents a major demand opportunity because Ayushman Bharat–Pradhan Mantri Jan Arogya Yojana expanded health coverage to approximately 500 million people, supporting diagnostic procedure access in secondary and tertiary hospitals. Brazil adds a significant Latin American expansion market, while GCC countries support regional demand through healthcare infrastructure investment. Japan and South Korea retain a technology-led role: Olympus brings established endoscopy capabilities to new single-use platforms, while South Korean adoption focuses on cases where contamination liability has been formally recognized.

Disposable Endoscopes Market Share & Competitive Landscape

The market is moderately concentrated. Ambu A/S, Boston Scientific Corporation, Olympus Corporation, Hoya Corporation through PENTAX Medical, and Karl Storz SE & Co. KG collectively held approximately 65% of global revenue in 2025. Ambu led with an estimated 30% share, supported by its broad single-use portfolio and platform-based account model. The remaining 35% is distributed among specialty competitors, including Verathon, Coloplast, CooperSurgical, Flexicare, RICHARD WOLF, and Chinese manufacturers.

Ambu’s position rests on bronchoscopy scale, coverage across urology, GI, laryngoscopy, and ENT, and its aView 2 Advance and aBox 2 digital platforms. Its Vizient agreement adds formulary reach in the United States. Management reaffirmed a 15–20% endoscopy-segment CAGR target through 2030 in January 2026. Boston Scientific competes most directly in single-use duodenoscopy through EXALT Model D, combining the device with GI accessories, stents, hemostasis products, and specialist relationships. FDA clearance for an updated EXALT Model D configuration in March 2025 reinforced its ERCP position.

Olympus faces a distinct transition: the company must protect a large reusable installed base while investing in single-use replacement categories. RenaFlex, cleared in April 2024, and the September 2025 MacroLux Medical distribution agreement show a partnership-led route into urology. Hoya’s PENTAX Medical business uses the ONE Pulmo bronchoscope as a European beachhead. Karl Storz targets critical care with the FIVE S 6.5, whose working-channel and suction performance serve an ICU-specific procurement requirement.

Major players operating in the disposable endoscopes market include:

• Ambu A/S: Single-use portfolio leader across bronchoscopy, urology, GI, video laryngoscopy, and ENT, centered on aView 2 Advance and aBox 2.

• Boston Scientific Corporation: EXALT-led GI and ERCP specialist with a broader procedural-accessory portfolio.

• Olympus Corporation: Reusable-endoscopy incumbent expanding through H-SteriScope, RenaFlex, and the MacroLux Medical partnership.

• Hoya Corporation (PENTAX Medical): Optics-led manufacturer using ONE Pulmo to build a single-use bronchoscopy position.

• Karl Storz SE & Co. KG: Endoscopy and minimally invasive surgery specialist focused on critical-care flexible endoscopy through FIVE products.

Recent Industry Developments

• Mar 2026: Karl Storz received FDA 510(k) clearance for the FIVE S 6.5 single-use bronchoscope, engineered with a 3.0 mm working channel for ICU and high-acuity emergency airway management. The launch strengthens competition where secretion management is a decisive clinical requirement.

• Feb 2026: LoopView received FDA 510(k) clearance for the B27-C single-use digital flexible bronchoscope. The clearance expands ICU-targeted bronchoscopy competition in North America.

• Jan 2026: Ambu reaffirmed a 15–20% CAGR target for its endoscopy segment through 2030 at the J.P. Morgan Healthcare Conference. The company identified gastroenterology as its next major penetration opportunity after bronchoscopy.